跳至主要内容
临床试验/IRCT20080901001165N65
IRCT20080901001165N65招募中3 期

Evaluation of effectiveness and safety of Detoxil capsules in controlling metabolic syndrome: A phase 3, randomized, placebo-controlled, double blind study

Tabib daru pharmaceutical company0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
25 years 至 75 years(—)
性别
All

入选标准

  • Patient should have read and signed the informed consent form
  • Patient should fulfill the criteria of NCEP ATP III for metabolic syndrome by having at least three items out of the following: 1- Fasting blood glucose higher than 100 mg/dL; 2- triglyceride level higher that 150 mg/dL; 3- HDL level lower than 40 mg/dL for men and 50 mg/dL for women; 4- systolic blood pressure higher than 130 mmHg or diastolic blood pressure higher than 85 mmHg; 5- waist circumference bigger than 102 cm for men and 94 cm for women

排除标准

  • Participation at a concurrent clinical trial
  • History of allergic reaction to any of the ingredients of drug
  • Active malignancy
  • Severe hepatic or renal disease

研究者

发起方
Tabib daru pharmaceutical company

相似试验